NEWS

Equita increased the target price of the GHC stock by 5% to 6.3 euros per share (from 5.8 euros), with implicit 9.5x EV/EBITDA 2024E. Confirming the rating on the stock at "BUY". In fact, following the communication of the 2003 results, analysts noted a solid trend in turnover for GHC with private activity growing. The indications given on the Aurelia Hospital project considered central to the equity story were particularly appreciated. Finally, analysts predict a supportive trend for accredited private healthcare operators, in the context of still long national healthcare system waiting lists to support GHC's organic growth, with the Aurelia deal having the potential to become a significant further driver of growth from 2024 onwards.